$USNA

Fleming John Turman sold $44K of USNA

Fleming John Turman sold 2,450 shares of USANA HEALTH SCIENCES INC (USNA) at $17.93 on 2026-06-01.

Original reporting
SEC EDGAR · Fleming John Turman
Published Jun 1, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$USNA
Neutral
medium confidence
Mentioned
$USNA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$USNANeutralLow
01

Why it matters

This is a disclosed ownership change (open-market sale) that can marginally affect sentiment but does not introduce new operational or financial information.

02

Market read

Traders may monitor USNA for any clustering of insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

Absence of a stated 10b5-1 plan does not prove bearish intent; traders should check for prior insider patterns and any concurrent buys/sales in the same window.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-01) after-hours/late session disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for USANA Health Sciences director Fleming John Turman.

Company-level read

Ticker impact

$USNANeutralMedium confidence
Context

USANA director Fleming John Turman sold 2,450 shares in an open-market transaction disclosed via SEC Form 4 today.

Expected impact

Likely limited, short-lived impact unless follow-on selling or broader negative news emerges.

Evidence & confidence

The filing provides a concrete datapoint (sale price/value and post-transaction holdings) but no new fundamentals, guidance, or event beyond ownership change.

Market effects

Minimal—single-company insider transaction without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing rather than a negative view, especially since the filing does not explicitly tie to performance or a corporate event.

Key entities

  • USANA HEALTH SCIENCES INC

    Subject of the insider transaction disclosure; director sold shares on 2026-06-01.

  • Fleming John Turman

    Director who sold 2,450 shares at $17.93/share; holdings after sale: 4,230 shares.

Related articles

$USNAHigh

USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsreleaseex991.htm EX-99.1 Document USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (N